REGENXBIO Says FDA Placed Clinical Hold On RGX-121 For Hunter Syndrome After Asymptomatic Spine MRI Findings In Five CAMPSIITE Participants; Does Not Expect To Resubmit BLA In Near Term
Share
Why It Matters
A medicine company hit a pause button on testing a new treatment for a rare disease because doctors found unexpected spine changes in some patients, even though they felt fine. When a company's medicine gets stopped for safety checks, people watch closely to see if the problem can be fixed or if it might take a long time.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.